Chimeric antigen receptor T-cell (CAR-T) therapy, already approved for certain blood cancers, is generating excitement in early tests against autoimmune diseases. Designed to wipe out a whole class of immune cells, the treatment holds promise but comes with potentially serious risks.
Leave a reply